Miramistin Darnytsia ointment 5 mg/g tube 30 g

Pharmacological properties

Pharmacodynamics. miramistin – the active pharmaceutical ingredient of the drug – belongs to surfactants of the cationoactive class. due to its chemical structure, the compound interacts with the lipid layer of the bacterial wall, which leads to the destruction of the membrane of the microorganism.

The spectrum of action of miramistin is wide and diverse. The pronounced bactericidal effect of miramistin is noted when it affects cocci (Mustafa and streptococci, including pneumococci) and gram-negative pathogens. Miramystin is characterized by high activity against microorganisms of both aerobic and anaerobic types, which form and do not form spores, as well as against large viruses (for example, herpes).

Miramistin has fungicidal properties. Dermatophytes, yeasts and fungi of the genus Candida, Ascomycetes, the causative agent of bran-like depriving, etc., are sensitive to it.

Of great interest is the activity of miramistin against associations of microorganisms and polyresistant hospital strains, as well as increasing the sensitivity of antibiotic-resistant strains when it is used.

Studies have established a significant inhibitory effect of miramistin on the formation of biofilms and already existing biofilms of such microorganisms as Staphylococcus aureus and β-hemolytic streptococcus group A.

The local effect of miramistin leads to increased regeneration of damaged tissues, improves the effect of treatment of chronic wounds.

The wide range of miramistin’s antimicrobial effect results in highly effective prevention of contamination of skin lesions (wounds, burns) during its use. The pronounced hyperosmolar effect of miramistin prevents the development of the inflammatory process in the wound and the surrounding area. Thanks to this property, purulent exudate is eliminated, selective dehydration of dead tissues with the formation of a dry scab is noted. At the same time, granulation tissue and healthy skin cells are not damaged, marginal epithelization processes are not inhibited.

Pharmacokinetics. Due to its physical and chemical properties, the ointment base of the drug affects the pathogens that are located both on the surface of the wound and in the tissues of the wound area. Thus, there is a possibility of penetration of a small amount of the active substance into the blood.

Indication

• Topical therapy of contaminated wounds of various location and origin; prevention of secondary contamination of wounds in the granulation phase; therapy of burns (II and IIIA degrees); ensuring readiness for the procedure of dermatoplasty of burn wounds; pyodermas caused by streptococci and staphylococci, fungal lesions of the skin and nails (dermatophytosis, onychomycosis), keratomycosis (including pityriasis versicolor), lesions of the skin and mucous membranes by fungi of the genus candida; in case of minor injuries received at home or at work, in order to prevent the development of complications of wound infection.

Application

For topical use in adult patients.

Therapy of wounds and burns. The drug is distributed directly over the area of ​​damaged skin, previously treated by generally accepted methods. Then a sterile gauze bandage is applied to the damaged treated area. It is possible to apply the ointment first to the dressing material, and then to the wound.

It is possible to fill the cavities of surgically treated purulent wounds or fistulas with ointment-soaked tampons or gauze turunds.

In the inflammatory phase, the ointment is used once a day, in the regeneration phase, the frequency of application is reduced to once every 1-3 days (depending on the condition of the wound). The dose of the drug is determined by the volume of the lesion and the severity of purulent exudation. The speed of the process of cleaning the wound and restoring damaged tissue affects the duration of therapy.

Infection of deeply located soft tissues requires the combined use of miramistin with systemic antibiotics, which determines the total duration of therapy.

Application in dermatology. Ointment 1-2 times a day is distributed in a thin layer on the affected skin or on the dressing material with subsequent application to the damaged areas. Therapy should be continued until negative microbiological test results are obtained. In the case of extensive damage to the skin by dermatophytes, it is allowed to use miramistin ointment for 5-6 weeks in combination with griseofulvin (or systemic fungicides). The presence of onychomycosis requires preliminary exfoliation of the affected nail plates.

Contraindication

Hypersensitivity to miramistin or other components of the drug.

Side effects

Occasionally, drug therapy for burns and trophic ulcers may be accompanied by minor smoking. this effect quickly disappears (within 15-20 seconds) involuntarily without the use of painkillers or discontinuation of the drug.

Hypersensitivity reactions are also likely (among other things rash, itching, hyperemia, dryness, dermatitis, skin maceration). The presence of propylene glycol in the preparation can lead to skin irritation.

Special instructions

Irrigation of the wound surface with a solution with antibacterial properties before applying the ointment increases the effectiveness of the drug.

In the case of wound contents of a purulent-necrotic nature, it is necessary to increase the amount of ointment used.

Since there is no significant data on the use of the drug during pregnancy and breastfeeding, it is necessary to consult a doctor before using it in this category of patients.

The drug is not used in children.

Miramistin ointment does not affect the speed of reaction when driving vehicles or working with machinery.

Interactions

Simultaneous topical use of surfactants of the anionic class with miramistin reduces its activity.

Miramistin helps to increase the sensitivity of microorganisms to antibiotics when it is used simultaneously with drugs of this group.

Overdose

No cases of overdose were found. however, in the case of distribution of miramistin ointment over a large area of ​​the skin, penetration of the active ingredients into the blood is possible. however, their quantity does not lead to toxic effects.

The systemic effect of miramistin is characteristic of surface-active substances of the cationoactive class, an increase in the bleeding period is possible.

Therapeutic measures in case of overdose include cancellation of treatment or reduction of the dose of the drug. Calcium preparations are used per os, Vikasol.

Storage conditions

At a temperature ≤25 °C in the original packaging.